Laddar...
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in p...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2008
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2721410/ https://ncbi.nlm.nih.gov/pubmed/19707382 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|